- Home
- SXC vs ANAB Comparison
SXC vs ANAB Comparison
Compare SXC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- ANAB
- Stock Information
- Founded
- SXC 1960
- ANAB 2005
- Country
- SXC United States
- ANAB United States
- Employees
- SXC N/A
- ANAB N/A
- Industry
- SXC Steel/Iron Ore
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- ANAB Health Care
- Exchange
- SXC Nasdaq
- ANAB Nasdaq
- Market Cap
- SXC 725.5M
- ANAB 621.1M
- IPO Year
- SXC N/A
- ANAB 2017
- Fundamental
- Price
- SXC $8.39
- ANAB $25.74
- Analyst Decision
- SXC Strong Buy
- ANAB Buy
- Analyst Count
- SXC 1
- ANAB 10
- Target Price
- SXC $13.00
- ANAB $44.25
- AVG Volume (30 Days)
- SXC 1.2M
- ANAB 534.2K
- Earning Date
- SXC 07-30-2025
- ANAB 08-04-2025
- Dividend Yield
- SXC 5.73%
- ANAB N/A
- EPS Growth
- SXC 51.30
- ANAB N/A
- EPS
- SXC 1.09
- ANAB N/A
- Revenue
- SXC $1,883,000,000.00
- ANAB $111,872,000.00
- Revenue This Year
- SXC N/A
- ANAB N/A
- Revenue Next Year
- SXC $0.99
- ANAB $24.39
- P/E Ratio
- SXC $7.69
- ANAB N/A
- Revenue Growth
- SXC N/A
- ANAB 387.20
- 52 Week Low
- SXC $7.47
- ANAB $12.21
- 52 Week High
- SXC $12.82
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- SXC 51.08
- ANAB 67.24
- Support Level
- SXC $8.27
- ANAB $23.10
- Resistance Level
- SXC $8.99
- ANAB $24.69
- Average True Range (ATR)
- SXC 0.25
- ANAB 1.34
- MACD
- SXC 0.06
- ANAB 0.11
- Stochastic Oscillator
- SXC 56.82
- ANAB 90.00
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).